CytoDyn Inc Banner Image

CytoDyn Inc

  • Ticker CYDY
    Exchange OTC More
  • Industry Biotechnology More
  • Sector Healthcare More
CytoDyn Inc Logo Image
  • 11-50 Employees
  • Based in Vancouver, Washington
CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn has beenMore working diligently to refile its Biologics License Application ("BLA") for this HIV combination therapy since receiving a Refusal to File in July 2020 and subsequently meeting with the FDA telephonically to address their written guidance concerning the filing.
4.8 / 5.0 (153)

CytoDyn Inc reports have an aggregate usefulness score of 4.8 based on 153 reviews.

CytoDyn Inc

Most Recent Annual Report

CytoDyn Inc
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

CytoDyn Inc Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!